Citius Oncology (CTOR) Stock Price, News & Analysis

Company Overview

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Key Stats

• Today's Range: $0.76 to $0.80
• 50-Day Range: $0.49 to $0.99
• 52-Week Range: $0.49 to $6.19
• Volume: 48,521 shs
• Average Volume: 71,935 shs
• Market Capitalization: $72.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

Citius Oncology Stock Analysis - MarketRank™

Citius Oncology scored higher than 44% of companies evaluated by MarketBeat, and ranked 701st out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Citius Oncology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Citius Oncology has a consensus price target of $6.00, representing about 669.2% upside from its current price of $0.78.

Amount of Analyst Coverage

Citius Oncology has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Citius Oncology is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Citius Oncology is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Citius Oncology has a P/B Ratio of 1.44. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.56% of the float of Citius Oncology has been sold short.

Short Interest Ratio / Days to Cover

Citius Oncology has a short interest ratio ("days to cover") of 4.47.

Change versus previous month

Short interest in Citius Oncology has recently decreased by 26.07%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Citius Oncology does not currently pay a dividend.

Dividend Growth

Citius Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.25

News Sentiment

Citius Oncology has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Citius Oncology this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 2 people have added Citius Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Citius Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.80% of the stock of Citius Oncology is held by insiders.

Percentage Held by Institutions

70.52% of the stock of Citius Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 6/06/2026
• Next Earnings (Estimated): 8/18/2026
• Fiscal Year End: 9/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CTOR
• Previous Symbol: NASDAQ:CTOR
• CIK: 1851484
• Web: www.citiusonc.com
• Phone: 347-627-0058
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Citius Oncology: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +669.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.76 million
• Net Margins: N/A
• Pretax Margin: -747.62%
• Return on Equity: -99.47%
• Return on Assets: -42.16%

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 0.50
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.54 per share
• Price / Book: 1.44

Miscellaneous

• Outstanding Shares: 92,980,000
• Free Float: 85,728,000
• Market Cap: $72.52 million
• Optionable: N/A
• Beta: 3.41